In addition, the use of the DAA-mediated treatment model allowed to confirm the hypothesis that treatment-driven viral eradication may be associated with the reduction of the analyzed markers levels in plasma, which occurred for sPD-1 and sLAG-3, regardless of the liver disease staging. The gene discussed is HOXD13; the disease is liver disorder.